Olaparib (AZD2281, Ku-0059436)Potent PARP1/PARP2 inhibitor CAS# 763113-22-0 |
- AZD2461
Catalog No.:BCC2214
CAS No.:1174043-16-3
- BYK 49187
Catalog No.:BCC2450
CAS No.:163120-31-8
- Rucaparib (free base)
Catalog No.:BCC4012
CAS No.:283173-50-2
- PJ34 hydrochloride
Catalog No.:BCC2210
CAS No.:344458-15-7
- Rucaparib (AG-014699,PF-01367338)
Catalog No.:BCC2207
CAS No.:459868-92-9
- A-966492
Catalog No.:BCC2211
CAS No.:934162-61-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 763113-22-0 | SDF | Download SDF |
PubChem ID | 23725625 | Appearance | Powder |
Formula | C24H23FN4O3 | M.Wt | 434.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | AZD2281; KU0059436 | ||
Solubility | DMSO : ≥ 33.33 mg/mL (76.72 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one | ||
SMILES | C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F | ||
Standard InChIKey | FDLYAMZZIXQODN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Olaparib (AZD2281, KU0059436) is a potent inhibitor of PARP1 and PARP2 with IC50 of 5 and 1 nM, respectively. | |||||
Targets | PARP1 | PARP2 | ||||
IC50 | 5 nM | 1 nM |
Cell experiment: [1] | |
Cell lines | Normal LCL cells ATM-null LCL cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reacting condition | 10 μM, 1 hour |
Applications | The sensitivity of cells to olaparib is mediated by absence of Ataxia Telangiectasia Mutated (ATM) activity. Immunoblot analysis revealed that in ATM wild-type LCLs, but not ATM null LCLs, phosphorylation of the ATM-dependent targets ATM S1981 and SMC1 S966 was induced in a dose-dependent manner by olaparib. |
Animal experiment: [1] | |
Animal models | Granta-519–engrafted NOD/SCID mice |
Dosage form | Intraperitoneal injection, 50 mg/kg/d, for 14 days |
Application | Analysis of the percentage of human CD45 staining by FACS analysis revealed a significant reduction in the percentage of Granta-519 cells in the bone marrow and a trend toward reduced tumor cell load in the spleen of mice treated with olaparib compared with those receiving vehicle alone. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Weston V J, Oldreive C E, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood, 2010, 116(22): 4578-4587. |
Olaparib (AZD2281, Ku-0059436) Dilution Calculator
Olaparib (AZD2281, Ku-0059436) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3017 mL | 11.5085 mL | 23.0171 mL | 46.0342 mL | 57.5427 mL |
5 mM | 0.4603 mL | 2.3017 mL | 4.6034 mL | 9.2068 mL | 11.5085 mL |
10 mM | 0.2302 mL | 1.1509 mL | 2.3017 mL | 4.6034 mL | 5.7543 mL |
50 mM | 0.046 mL | 0.2302 mL | 0.4603 mL | 0.9207 mL | 1.1509 mL |
100 mM | 0.023 mL | 0.1151 mL | 0.2302 mL | 0.4603 mL | 0.5754 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Olaparib (4-(3-4-fluorophenyl) methyl-1(2H)-one), as known as AZD2281 or KU0059436, is a novel, selective and potent inhibitor of both poly adenosine diphosphate-ribose polymeras-1 (PARP-1) and poly adenosine diphosphate-ribose polymeras-2 (PARP-2). Having been successfully used in the treatment of tumors harboring BRCA mutations, olaparib strongly inhibits the growth of BRCA2-deficient mouse mannary tumor cell lines demonstrating cytotoxicity. In previous researches treating non-small cell lung carcinoma (NSCLC), olaparib increased the radiation sensitivity of NSCLC cells, grown as xenografts in nude mice, following radiation and increased vascular perfusion in Calu-6 tumors established in a dorsal window chamber (DWC) model.
Reference
Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O’Connor, Stephen R. Wedge, and Ian J. Stratford. Inhibition of poly(ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011; 10(10): 1949-1958
Bastiaan Evers, Rinske Drost, Eva Schut, Michiel Bruin, Eline vab der Burg, Patrick W.B. Derksen, Henne Holstege, Xiaoling Liu, Ellen van Drunen, H. Berna Beverloo, Graeme C. M. Smith, Niall M. B. Martin, Alan Lau, Mark J. O’Connor, and Jos Jonkers. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and Cisplatin. Clin Cancer Res 2008; 14:3916-3925
- Polyphyllin G
Catalog No.:BCN1054
CAS No.:76296-75-8
- Polyphyllin F
Catalog No.:BCN2589
CAS No.:76296-74-7
- Polyphyllin E
Catalog No.:BCN2588
CAS No.:76296-73-6
- Polyphyllin II
Catalog No.:BCN1052
CAS No.:76296-72-5
- Polyphyllin C
Catalog No.:BCN2587
CAS No.:76296-71-4
- 7-Deoxy-10-hydroxyloganetin
Catalog No.:BCN7578
CAS No.:76267-48-6
- Fmoc-Met(O)-OH
Catalog No.:BCC3530
CAS No.:76265-70-8
- Fmoc-Lys(Tfa)-OH
Catalog No.:BCC3524
CAS No.:76265-69-5
- Yukovanol
Catalog No.:BCN3699
CAS No.:76265-12-8
- Piptocarphin A
Catalog No.:BCN4586
CAS No.:76248-63-0
- 15-Hydroxyferruginol
Catalog No.:BCN3294
CAS No.:76235-93-3
- Ehretinine
Catalog No.:BCN1994
CAS No.:76231-29-3
- Sodium Nitrite
Catalog No.:BCC4723
CAS No.:7632-00-0
- DL-AP5
Catalog No.:BCC6552
CAS No.:76326-31-3
- Latrunculin A
Catalog No.:BCC7830
CAS No.:76343-93-6
- (1S)-(+)-Menthyl chloroformate
Catalog No.:BCN4972
CAS No.:7635-54-3
- Euphorbia factor Ti2
Catalog No.:BCN3782
CAS No.:64180-96-7
- Dihydroxyaflavinine
Catalog No.:BCN7387
CAS No.:76410-56-5
- Sodium chloride
Catalog No.:BCC7580
CAS No.:7647-14-5
- Cesium chloride
Catalog No.:BCC2399
CAS No.:7647-17-8
- Effusanin E
Catalog No.:BCN3234
CAS No.:76470-15-0
- Effusanin B
Catalog No.:BCN3391
CAS No.:76470-16-1
- Kuwanon H
Catalog No.:BCN2945
CAS No.:76472-87-2
- Morachalcone A
Catalog No.:BCN4311
CAS No.:76472-88-3
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.[Pubmed:25975349]
Int J Oncol. 2015 Jul;47(1):262-8.
PARP inhibitors are considered promising anticancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Veliparib), BSI-201 (Iniparib) and AZD228 (Olaparib) in breast cancer cell lines with BRCA1 or BRCA2 mutations and 9 different BRCA wild-type cell lines with BRCA1 allelic loss. We found that AZD2281 was the most potent in the PARP inhibitors and induces significant growth inhibition (~95%) in BRCA1 mutant (HCC1937, MDA-MB-436, and SUM-149PT) and BRCA2 mutant (HCC1428) cell lines. AZD2281 treatment also resulted in growth inhibition ranging from 20 to 50% in cells with BRCA1 allelic loss, including ER(+), HER2/Neu(+) and triple-negative breast cancer (TNBC) cells, but showed no effect in cells without with type BRCA without allelic loss. Knocking down of BRCA1 or BRCA2 in TNBC cells with BRCA1 allelic loss by RNA interference significantly enhanced AZD2281-induced growth inhibition and induced significant autophagy that was associated with mitophagy in cells with BRCA mutations. Inhibition of autophagy by gene knockdown significantly diminished AZD2281-induced mitophagy and apoptosis, indicating that autophagic process mediates some of the downstream effects of PARP inhibitors. In conclusion, our data provide the first evidence of PARP inhibitor AZD2281 autophagy and mitophagy in breast cancer cell lines with BRCA mutations or BRCA-allelic loss. In addition, our results indicate that the patients with BRCA1 allelic loss may also benefit from PARP inhibitor therapy if BRCA is further inhibited.
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.[Pubmed:26975633]
Cancer Lett. 2016 Jun 1;375(2):313-322.
APR-246 (PRIMA-1(Met)) is able to bind mutant p53 and restore its normal conformation and function. The compound has also been shown to increase intracellular ROS levels. Importantly, the poly-[ADP-ribose] polymerase-1 (PARP-1) enzyme plays an important role in the repair of ROS-induced DNA damage. We hypothesize that by blocking this repair with the PARP-inhibitor AZD2281 (olaparib), DNA damage would accumulate in the cell leading to massive apoptosis. We observed that APR-246 synergistically enhanced the cytotoxic response of olaparib in TP53 mutant non-small cell lung cancer cell lines, resulting in a strong apoptotic response. In the presence of wild type p53 a G2/M cell cycle block was predominantly observed. NOXA expression levels were significantly increased in a TP53 mutant background, and remained unchanged in the wild type cell line. The combined treatment of APR-246 and olaparib induced cell death that was associated with increased ROS production, accumulation of DNA damage and translocation of p53 to the mitochondria. Out data suggest a promising targeted combination strategy in which the response to olaparib is synergistically enhanced by the addition of APR-246, especially in a TP53 mutant background.
The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.[Pubmed:24577941]
Mol Cancer Ther. 2014 May;13(5):1170-80.
Potent application of topoisomerase I inhibitor plus PARP inhibitor has been suggested to be an effective strategy for cancer therapy. Reportedly, mismatch repair (MMR)-deficient colon cancer cells are sensitive to topoisomerase I inhibitor, presumably due to microsatellite instability (MSI) of the MRE11 locus. We examined the synergy of SN-38, an active metabolite of irinotecan, in combination with the PARP inhibitor olaparib in colon cancer cells showing different MMR status, such as MSI or microsatellite stable (MSS) phenotype. Treatment with SN-38 and olaparib in combination almost halved the IC50 of SN-38 for a broad spectrum of colon cancer cells independent of the MMR status. Furthermore, olaparib potentiated S-phase-specific double-strand DNA breaks (DSB) induced by SN-38, which is followed by Rad51 recruitment. siRNA-mediated knockdown of Rad51, but not Mre11 or Rad50, increased the sensitivity to olaparib and/or SN-38 treatment in colon cancer cells. In vivo study using mouse xenograft demonstrated that olaparib was effective to potentiate the antitumor effect of irinotecan. In conclusion, olaparib shows a synergistic effect in colon cancer cells in combination with SN-38 or irinotecan, potentiated by the Rad51-mediated HR pathway, irrespective of the Mre11-mediated failure of the MRN complex. These results may contribute to future clinical trials using PARP inhibitor plus topoisomerase I inhibitor in combination. Furthermore, the synergistic effect comprising topoisomerase I-mediated DNA breakage-reunion reaction, PARP and Rad51-mediated HR pathway suggests the triple synthetic lethal pathways contribute to this event and are applicable as a potential target for future chemotherapy.
Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.[Pubmed:24534203]
Cancer Lett. 2014 Jun 28;348(1-2):20-8.
In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. While both agents were able to cause growth arrest and limited apoptosis, the combination of the two was able to synergistically cause growth arrest and non-apoptotic cell death. Furthermore, in an in vivo xenograft model, the combination caused substantially increased tumor necrosis compared to either treatment alone. Our results support further investigation of the combination of Bcl-2 and PARP inhibitors for the treatment of pancreatic cancer.